To study the oncogenic activity of cyclin E in an in vivo system we generated transgenic mice expressing high levels of cyclin E in T-lymphocytes by using a construct containing the CD2 locus control region. These animals were neither predisposed to develop any tumors spontaneously nor showed an increased incidence when crossbred with Em L-myc transgenic mice but developed hyperplasia in peripheral lymphoid organs at later age with an incidence of 27%. When treated with the DNA methylating carcinogen N-methylnitrosourea (MNU) that provokes the development of T-cell lymphomas, CD2-cyclin E transgenic animals came down with T-cell neoplasia showing a signi®cant higher incidence (54%) than normal non transgenic controls (31%). In one of eight tumors that arose in normal MNU treated mice we could ®nd an expected activating point mutation in the Ki-ras gene (12.5%). In contrast, the same mutation occurred in ®ve of 16 tumors from CD2-cyclin E transgenic mice (31.2%). Whereas cyclin E overexpression alone did not lead to an increased CDK2 activity we observed in all tumors that emerged from either MNU treated normal mice or treated CD2-cyclin E transgenics a downregulation of p27 KIP1 and a higher histone H1 kinase activity in CDK2 immunoprecipitates compared to normal tissue. These ®ndings demonstrate that high level expression of cyclin E can predispose T-cells for hyperplasia and malignant transformation. However, the results also suggest that this activity of cyclin E is manifest only when other cooperating oncogenes in particular ras genes are present and activated. This would be consistent with our previous ®nding that cyclin E and Ha-Ras cooperate in focus formation assays in rat embryo ®broblasts.
Introduction D-and E-type cyclins and their associated catalytic subunits CDK4, CDK6 and CDK2 control progression through the G1 phase of the cell cycle (Sherr, 1993; Ohtsubo et al., 1995; Alevizopoulos et al., 1997; Dulic et al., 1992; Ko et al., 1992) . The expression of Dand E-type cyclins as well as CDK4 during early G1 depends on the presence of mitogens (Sherr, 1993; Sewing et al., 1993; Ko et al., 1992) . One of the substrates of D-type cyclin/CDK4 complexes and later in G1 of the cyclin E/CDK2 kinase is the tumor suppressor protein Rb (Morgan, 1995; Ko et al., 1992; Planas-Silva and Weinberg, 1997) which is active in its non phosphorylated or hypophosphorylated form and becomes hyperphosphorylated by cyclin/CDK complexes (Planas-Silva and Weinberg, 1997; Zarkowska and Mittnacht, 1997; Bartek et al., 1996) .
Phosphorylation inactivates Rb and leads to the release of E2F family transcription factors from their binding to Rb which in turn activate a set of target genes that are essential for entry into S phase (Ohtsubo et al., 1995; Ohtnai et al., 1995; DeGregori et al., 1995; Weinberg, 1996) . At the end of the G1 phase and at the G1-S transition cyclin E/CDK2 complexes are activated and complete the phosphorylation of Rb and other pocket proteins. However, cyclin E/CDK2 complexes may have an alternative function that may also be important for cell cycle progression because cells harboring a non phosphorylable Rb mutant are still able to progress from G1 to S phase upon arti®cial activation of cyclinE/CDK2 (Lukas et al., 1997) .
A number of inhibitors for cyclin dependent kinases (CKIs) among them the proteins p16 INK4a , p21 WAF1 , and p27 KIP1 function as an additional layer of regulation and control G1 progression (Sherr and Roberts, 1995; Harper and Elledge, 1996; Reynisdottir et al., 1995; Polyak et al., 1994) . The proteins p21 WAF1 and p27 KIP1 bind to cyclin D1 and cyclin E and block the activity of the respective cyclin/CDK complexes. On the other hand, p16 INK4a speci®cally inhibits CDK4 and CDK6, both catalytic subunits of D-type cyclins (Hall et al., 1995) . Recently, a more complex picture has emerged for p21
WAF1 that identi®es this protein not only as an inhibitor of D-and E-type kinase complexes but also as a necessary assembly factor and part of a tetrameric complex involving PCNA (LaBear et al., 1997 and references therein) .
Cyclin E is overexpressed in a number of human tumors (for an overview see Donnellan and Chetty, 1999) . In particular, high levels of cyclin E have been correlated with poor prognosis in breast cancer (Buckley et al., 1993; Keyomarsi et al., 1995; Keyomarsi and Pardee, 1993) and one study with transgenic mice suggested a functional role of elevated cyclin E levels in malignant transformation of mammary tissue (Bortner and Rosenberg, 1997) . In addition, in several types of leukemias cyclin E overexpression was detected and appeared to correlate with low rates of complete remission and disease free survival. Also, chronic lymphocytic leukemia, Hodgkin's and Non-Hodgkin's lymphoma were found to express elevated cyclin E levels (Wolowiec et al., 1995; Erlanson et al., 1998) . However, whether cyclin E levels are functionally involved in lymphomagenesis has not been investigated. In this study we present a transgenic mouse model where we have addressed this question by targeting high level cyclin E expression to T-cells using the CD2 locus control region. We can show that elevated cyclin E levels can contribute to the process of T-cell lymphomagenesis when this process is initiated by a carcinogen.
Results

Targeted expression of cyclin E in the T-cell compartment of transgenic mice
We have used the CD2 locus control region to generate a transgenic mouse model with high levels of cyclin E expression targeted to the T-lymphoid lineage. A construct was generated in which the human cyclin E cDNA (Ko et al., 1991) was placed between the CD2 promoter and the CD2 minigene (Zhumabekov et al., 1995) (Figure 1a ). The insert was freed from vector sequences and injected into fertilized oocytes from (C57/B166C3H) F1 female mice as described (Hogan et al., 1994) . Three founder were obtained and were used to establish three independent CD2-cyclin E transgenic lines (line 461, line 834 and line 582). Animals from all three transgenic lines expressed the hcyclin E transgene in all lymphoid tissues (Figure 1b) . The development of early T-cells, thymic architecture and thymic subpopulations as well as their sensitivity towards apoptotic stimuli as dexamethasone treatment or DNA-damage were not detectably altered in CD2-cyclin E transgenic mice compared to wild type controls (data not shown). Next, the analysis of immunoprecipitates prepared with an anti hcyclin E antibody from thymocytes showed that all three transgenic lines expressed a functional hcyclin E that is able to associate with CDK2 and to activate its kinase activity on histone H1 as a substrate ( Figure  2a ). In addition, Western analysis showed the presence of CDK2 in anti cyclin E immunoprecipitates ( Figure  2a ). However, anti CDK2 immunoprecipitates did not reveal higher total histone H1 kinase activity in transgenic thymocytes when compared to non transgenic controls (Figure 2a ) although the endogenous CDK2 is clearly associated with the transgenic cyclin E protein. Similarly, levels of p27 KIP1 were not altered by transgenic hcyclin E expression in thymocytes but Western blot analysis of anti hcyclin E immunoprecipitates showed that most if not all p27 KIP1 molecules are associated with the hcyclin E expressed from the transgene (Figure 2b ). Expression levels of pocket proteins pRb, p130 or p107 were not altered in thymi of hcyclin E transgenic mice albeit in the case of Rb were present at variable levels ( Figure 3a) .
Cell cycle progression of T-lymphocytes upon antigenic activation is enhanced through high levels of cyclin E Staining of ethanol ®xed thymocytes from transgenic mice and controls with DNA dyes showed that the relative percentages of cells that fall into the dierent cell cycle phases was unaected by the expression of exogenous hcyclin E (Figure 3b) . Similar results were obtained for peripheral T-cells isolated from spleen or lymph nodes (not shown). By contrast, when mature resting T-cells isolated from spleens of CD2-cyclin E transgenic mice were stimulated with either a combination of anti CD3 and anti CD28 antibodies or with phorbol ester (TPA) and ionomycin, they started to proliferate earlier and with a slightly higher rate of thymidine incorporation relative to cells from control animals (Figure 4a,b) . In addition, contrary to thymocytes, peripheral T-cells from CD2-cyclin E transgenic mice showed a much higher level of p27 KIP1 than normal T-cells and a very fast downregulation of p27 KIP1 already after 6 h of stimulation when p27 KIP1 levels of normal T-cells have not yet begun to fall (Figure 4c) . Further, the levels of p21 WAF1 appear also to depend on the expression of the exogenous transgenic cyclin E because p21 WAF1 is not upregulated to the same level after stimulation for 16 h as was found in normal control T-cells (Figure 4c ).
CD2
-cyclin E transgenic mice are predisposed for lymphoid hyperplasia and carcinogen induced lymphomagenesis A population of 15 CD2-cyclin E transgenic mice from all three lines were observed over a period of 52 weeks without any manifestation of lymphoid malignancy. However, four cases of lymphoid hyperplasia were found during the aging of this population (27%) that was manifest in these animals by the appearance of enlarged lymph nodes and spleen. Closer analysis of the rearrangement of the T-cell receptor b-locus from these organs excluded a clonal origin and thus malignancy of the observed hyperplasia (data not shown).
As we did not observe any spontaneous malignancy in CD2-Cyclin E transgenic mice, we crossbred the CD2-cyclin E transgenic mice with Em L-myc , 1990) which have already been a useful tool in our lab to demonstrate the oncogenic cooperation between myc genes and putative oncogenes including cyclin D1, e.g. (Lovec et al., 1994) . Among a population of 11 CD2-cyclin E/Em L-myc double transgenic animals none developed a tumor within an observation period of 300 days pointing to a lack of cooperation between cyclin E and Myc family members in lymphomagenesis.
Next we tested whether the presence of high levels of cyclin E can alter the susceptibility towards a carcinogen. Thirty-nine CD2-cyclin E transgenic mice and 29 non- Figure 2 (a) Extracts from normal thymocytes (non tg) and from CD2-cyclin E transgenic mice comprising all three lines were separated by SDS ± PAGE and the indicated proteins were detected by Western blotting, immuno-precipitation or a combination of both as indicated. IPs were done with the anti-CDK2 or anti-cyclin E antibodies, that react with the transgenic human cyclin E. Precipitated proteins as well as supernatants (Sup) were checked with the indicated reagents. IPs with anti-CDK2 were also used to measure Histone H1 kinase activity. The transgenic cyclin E was able to activate the endogenous CDK2 kinase. (b) The level of p27 KIP1 was not changed in thymocytes from transgenic mice compared to controls. The IP experiments suggests also that all p27 KIP1 molecules are associated with cyclin E expressed from the transgene Figure 3 (a) Extracts from normal thymocytes (non tg) and from CD2-cyclin E transgenic mice comprising all three lines were separated by SDS ± PAGE and the indicated proteins were detected by Western blotting. (b) Thymocytes from the indicated sources were prepared, ®xed in ethanol and stained with propidium iodide. The percentage of cells in G1, S and G2/M phases were measured by FACS analysis transgenic age matched littermates were treated with a single dose of the carcinogen N-methylnitrosourea (MNU) which provokes the formation of T-cell lymphoma (Joshi and Frei, 1970; Liu et al., 1994) . Lymphoid neoplasms appeared in thymus, lymph nodes and spleen in both groups of animals as expected. Strikingly, a much higher incidence (54%) was observed in the CD2-cyclin E transgenic mice than in the nontransgenic control mice (31%, Figure 5 ). However, both groups succumbed with tumors within about the same latency period of 124 days ( Figure 5 ). All tumors were found to be malignant neoplasms judged by the presence of discreet TCR b locus rearrangements in the genome of the tumor cells. This was tested by Southern blotting of genomic tumor DNA and hybridization with a Jb2 probe as described before (MoÈ roÈ y et al., 1990). In addition, the identi®cation of these malignancies as T-cell lymphomas was veri®ed by staining the cells for the presence of typical surface markers as CD4, CD8, Thy1.2, B220 (Table 1) .
High incidence of Ki-ras activation in MNU induced lymphoid tumors from CD2 cyclin E transgenic mice
The alkylating agent MNU has been described before to interact with guanine producing several modi®ed bases leading to point mutations after DNA repair and thus activation of oncogenes as Ki-ras (e.g. Newcomb et al., 1989 Newcomb et al., , 1995 ). Therefore we have tested the incidence of Ki-ras codon 12 mutations in tumors from CD2-cyclin E transgenic mice and non transgenic mice employing a PCR strategy that allows to Figure 4 Peripheral T-cells from CD2-cyclin E transgenic mice were prepared and stimulated by treatment with (a) 10 mg/ml anti-CD3 and 2 mg/ml anti-CD28 or (b) by a mixture of 1 ng/ml phorbolester (TPA) and 0.2 mg/ml ionomycin in the presence of 3 Hthymidine. Samples were taken at the indicated time points over a period of 80 h and the rate of incorporated labeled thymidine was measured. Shown are means of triplicate experiments with standard deviations. Cells from two independent lines of CD2-cyclin E transgenic lines appear to proliferate better when stimulated compared to controls. (c) Another set of samples was taken over a period of 3 ± 16 h after stimulation with anti CD3/CD28 and extracts were analysed by Western blotting. Extracts derived from Tcells of CD2-cyclin E transgenics show altered kinetics and levels of p27 KIP1 and p21
WAF1
Oncogenic potential of cyclin E H Karsunky et al distinguish between a mutated and a wild type Ki-ras allele. Tumors from CD2-cyclin E transgenic mice show a higher rate of Ki-ras mutations (5/16, 31.2%) than tumors from non transgenic controls (1/8, 12.5%) (Figure 6a, b) . This suggests an oncogenic cooperation between cyclin E and Ras in vivo and con®rms our earlier observation that high levels of cyclin E are able to cooperate very eciently with an activated Ha-ras gene in the malignant transformation of rat embryo ®broblasts (Haas et al., 1997) .
MNU induced lymphoid tumors contain low levels of p27 KIP1 and high cyclin E associated histone H1 kinase activity Extracts from thymi and tumors from both CD2-cyclin E transgenic and non transgenic mice were analysed by Western blotting. Whereas the level of CDK2 was not grossly altered, the levels of p27 KIP1 were clearly reduced in tumors compared to non-transformed thymocytes (Figure 7) . In addition, immunoprecipitates prepared from thymi and from tumors from transgenic and non transgenic animals with an anti-CDK2 antibody showed signi®cantly elevated levels of histone H1 kinase in tumor cells compared to normal non transformed cells (Figure 7 ). Lower levels of p27 KIP1 and elevated CDK2 associated kinase activity were found in tumors from both transgenic and non transgenic animals and also in a cell line derived from a spontaneous T-cell lymphoma that developed in a p53 de®cient mouse and was included in the analysis (Figure 7 ). This demonstrated that a downregulation of p27 KIP1 levels and elevated levels of CDK2 associated kinase activity correlate with the process of lymphomagenesis itself and are independent of the speci®c mechanisms that may have been responsible for the development of a tumor.
Discussion
High levels of cyclin E have been detected in various human tumors, but the signi®cance of this overexpression is unclear. To shed more light on the role T  T  T  T  T  T  T  T  T  T  T  T  T  T  T  T  T  T  T  T  T  T  T  T  T  T Single cell suspension from tumor samples were stained with directly labeled anti-CD4, anti-CD8, anti-Thy 1.2 or anti-B220 antibodies according to standard procedures as described before (Schmidt et al., 1998) . The rearrangements of the T-cell receptor b locus was determined by Southern blot analysis of DNA directly prepared from tumor tissue using a Jb2 probe as described previously (MoÈ roÈ y et al., 1990). Preparation of genomic DNA from tumor samples, the blotting procedures and the probe used have been previously described (MoÈ roÈ y et al., 1990). Jb2 R : TCR b chain rearranged. The latency period for tumor appearance (DT) is given in days (d) of cyclin E expression levels in the emergence of lymphoid tumors we have generated a transgenic mouse model in which cyclin E overexpression was targeted to T-lymphocytes. We could show that the overexpressed cyclin E associates with CDK2 and p27 KIP1 in thymocytes from these animals and that the transgenic cyclin E is functional and can activate CDK2 to phosphorylate histone H1. Although cyclin E overexpression alone is not sucient to induce higher CDK2 kinase activity which is in agreement with previous data from in vitro systems (Sgambato et al., 1996; Sweeney et al., 1998) . In culture, serum starved ®broblasts can be driven from G0 into S phase by serum and this process can be accelerated by overexpression of cyclin E (Resnitzki and Reed, 1995) . Our studies in transgenic mice display a similar situation: resting T-lymphocytes and thymocytes remain in G1/G0 phase regardless of cyclin E expression. When stimulated, T-cells from CD2-cyclin E transgenic mice enter S phase more rapidly than cells from non transgenic animals. It seems conceivable that this eect of cyclin E overexpression on cell cycle progression may lay the ground for a malignant transformation. However, cyclin E overexpression alone does not lead to the development of lymphoma in CD2-cyclin E transgenic mice pointing to the possibility that antigenic stimulation and high levels of cyclin E are not sucient for lymphomagenesis even after longer latency periods. Interestingly however, CD2-cyclin E transgenic mice develop swelling of peripheral lymphoid organs that were clearly of polyclonal origin. Closer analysis did not reveal the systematic expansion of a particular cell type indicating a general lymphoproliferative status. In this respect, the CD2-cyclin E transgenic mice generated here are similar to others with targeted expression to mammary epithelial cells (Bortner and Rosenberg, 1997) . These mice also developed a hyperplastic phenotype but which in contrast to the CD2-cyclin E transgenics was followed by the development of tumors. The emergence of a lymphoid hyperplasia indicates that high levels of cylin E could represent a prerequisite of malignancy that requires speci®c mutations in complementary pathways to develop into a full malignancy.
Surprisingly, Myc family genes cannot initiate such a complementary pathway because here, we did not observe a cooperation between cyclin E and L-Myc in lymphomagenesis. This ®nding contrasts strongly with the eects of cyclin D1 in the malignant transformation of lymphocytes. In this case, the presence of a transcriptionally activated N-or L-Myc allele strongly accelerated B-cell lymphomagenesis in Em-cyclin D1 transgenic animals (Lovec et al., 1994) . Due to the small number of CD2-cyclin E/Em L-myc double transgenic mice we have generated we cannot rule out a possible weak cooperation between Myc genes and cyclin E. Nevertheless, a strong cooperative eect, as the one we have observed between cyclin D1 and Myc (Lovec et al., 1994) , can be excluded for cyclin E. Furthermore, this ®nding points to dierent functions of cyclin D1 and cyclin E during tumorigenesis and in particular in lymphomagenesis beyond the upregulation of their respective CDK complex partner.
Treatment of mice with MNU can provoke the formation of lymphoid tumors and induce speci®c mutations in the Ki-ras gene. Our data from such an experiment with CD2-cyclin E transgenic mice clearly showed that high levels of cyclin E correlate with a higher incidence of MNU induced lymphoid tumors in transgenic animals when compared to non transgenic mice of the same age. In addition, tumors from the transgenic mice showed a higher rate of activating Kiras codon 12 mutations than non-transgenic controls. We had previously shown that primary ®broblasts can be malignantly transformed with high levels of cyclin E and in the presence of an activated Ha-ras protein.
Thus, a higher rate of Ki-ras mutations in MNU induced tumors from CD2-cyclin E transgenic mice than normal mice would support the concept that cyclin E depends on Ras initiated signal transduction pathways to be able to malignantly transform a cell in vivo. Clearly, a number of other mutations are generated by the treatment with MNU that have not been identi®ed here and that may also be important for cyclin E mediated tumorigenesis. However, the presence of high levels of cyclin E and an activating mutation in a ras gene can be interpreted as a strong selective advantage for a cell to develop into a fully malignant tumor, suggesting that cyclin E and Ras initiated pathways cooperate eciently in tumorigenesis. Figure 6 Detection of Ki-ras mutations. (a) Scheme of the PCR strategy used to detect Ki-ras codon 12 mutations in thymic T-cell tumors and agarose gel electrophoresis of PCR products obtained from thymic T-cell tumors in which both Ki-ras alleles were wild type (wt/wt), one wild type allele and one mutated allele (wt/mut) or both alleles mutated (mut/mut) for codon 12 G to A mutations. Using the depicted primers (20mers), the wild type Ki-ras gene (wt) gives rise to a fragment of 86 bp after digestion with BstNI. The mutated allele (mt) is not cut by BstNI and produces a fragment of 106 bp. (b) The percentage of tumors with Ki-ras mutations is higher in tumors from CD2-cyclin E transgenic mice than in tumors from normal mice Given the importance of some G1 speci®c inhibitors of cell cycle progression in tumorigenesis, one possibility how elevated G1 cyclin expression contributes to tumorigenesis is the sequestering of p21 WAF1 or p27 KIP1 inhibitors and subsequently a higher endogenous cyclin/CDK kinase activity. This could not be observed in the transgenic model system presented here. Rather, we ®nd that in thymocytes of CD2-cyclin E transgenic mice apparently a high percentage of p27 KIP1 is associated with the transgenic cyclin E protein, without ensuing a higher total histone H1 kinase activity in CDK2 immunoprecipitates. In addition, peripheral T-cells from CD2-cyclin E transgenic mice showed a higher p27 KIP1 level in G1/G0 than normal controls which is again in agreement with data from an in vitro system (Sgambato et al., 1996) . This suggests, that higher levels of cyclin E may lead at least in peripheral Tcells to a stabilization of p27 KIP1 possibly by preventing p27 KIP1 degradation via the proteasome pathway by association with cyclin E.
Peripheral T-cell do not express readily detectable amounts of p21 WAF1 . It has been shown that upon antigenic stimulation the levels of p21 WAF1 rise in Tcells while they are entering the cell cycle (Nourse et al., 1994) . One remarkable feature of CD2-cyclin E transgenic mice is that p21 WAF1 levels do not rise to the same level as wild type T-cells. While the mechanism of this disregulation of p21 WAF1 has still to be determined, lower p21 WAF1 levels could represent a contribution for the accelerated S phase entry of CD2-cyclin E transgenic T-cells. In addition to elevated levels of cyclin E in tumors the status of p27 KIP1 has been correlated in a number of studies with outcome of disease and a low level of p27 KIP1 generally indicates poor prognosis. One study in particular has quanti®ed cyclin E and p27 KIP1 levels in 105 patients with malignant lymphoma and found that high levels of cyclin E and low level of p27 KIP1 were associated with poor disease outcome (Erlanson et al., 1998) . Interestingly, the study showed that p27 KIP1 expression was a signi®cant, independent prognostic factor for malignant lymphoma. Our model oered the possibility to verify this hypothesis in an in vivo situation and con®rmed that in all lymphoid tumors from MNU treated normal and CD2-cyclin E transgenic animals p27 KIP1 was either absent or downregulated compared to levels found in normal thymic T-cells. Accordingly, all tumors showed a higher level of histone H1 kinase activity in CDK2 immunoprecipitates compared to normal cells indicating that the loss of p27 KIP1 expression may be a prerequisite or at least a strong contributor to lymphomagenesis.
We have developed an in vivo model for cyclin E overexpression within the lymphoid compartment. The results obtained argue for a role of cyclin E as a contributor in the process of lymphomagenesis and strengthen a role of Ras initiated pathways as cooperating events in cyclin E associated tumorigen- Figure 7 Analysis of cell extracts from normal thymocytes (non tg) and from tumors that arose in normal mice and CD2-cyclin E transgenics after MNU treatment. Whereas the level of CDK2 remained unchanged the expression of p27 KIP1 was downregulated in tumors in comparison to controls. In addition CDK2 kinase activity was signi®cantly increased in tumors from both transgenic and normal mice. Equal loading and proper transfer of proteins were routinely checked by Ponceau staining. All samples were run on the same gel in parallel; samples from tumors and from prelymphomatous mice were separated for clarity. Cell lines 2604 and 2608 were established from MNU induced thymic lymphomas that arose in CD2-cyclin E transgenic mice. Line 5245 was established from a spontaneous thymic lymphoma that arose in a p53 7/7 mouse and was used as a control esis. The study clari®es that cyclin E is not a strong oncoprotein in lymphoid cells but that overexpression of cyclin E can worsen a predisposition for lymphomagenesis provoked by other stimuli in particular DNA damaging substances.
Materials and methods
Transgenic mice
All transgenic mice used in this study were generated from ovae obtained from an F1 (C57/B166C3H) background as described (Hogan et al., 1994) and transgenic lines were kept by crossbreeding with C57/B16 animals. The CD2-cyclin E transgenic mice analysed here represent the third generation obtained upon backcrossing the founder animals.
Molecular analyses and probes
Preparation of genomic DNA from tail tips and tumor samples was performed as previously described (Hogan et al., 1994) . DNA blotting procedures were performed as described elsewhere (Sambrook et al., 1989) . The Jb2 probe that was used to detect TCRb rearrangements is a 1.9 kb HindIIIBamHI fragment containing the Jb locus as described (MoÈ roÈ y et al., 1990) . For the genotyping of CD2-cyclin E transgenic mice the human cyclin E cDNA was used as a probe in Southern blot analysis on tail tip derived DNA digested with BamHI.
Flow cytometry
Single cell suspensions were prepared as described (MoÈ roÈ y et al., 1993) at the time of autopsy from spleen, thymus or lymph nodes in PBS supplemented with 0.5% FCS (staining solution). Cells were washed in this solution and incubated on ice for 30 min with antibodies directly conjugated with uorochromes (all antibodies supplied from Pharmingen). Cells were washed twice in staining solution after the incubation and examined with a FACSCalibur (BectonDickinson). For propidium iodide staining cells were washed once with cold PBS and ®xed with ethanol overnight at 48C. Cells were collected and then incubated in 2 mg/ml propidium iodide (Sigma) in PBS/RNaseA (10 mg/ml) for 30 min at room temperature in the dark.
T-cell stimulation and 3 H-thymidine incorporation T cells were puri®ed from single cell suspensions of spleens using a mouse T-cell enrichment column kit (R&D Systems) based on a high-anity negative selection according to the supplier's protocol. 96-well plates were coated with 10 mg/ml anti-CD3 (145-2C11) and 2 mg/ml anti-CD28 (37.51, both Pharmingen) or 1 ng/ml TPA and 0.2 mg/ml ionomycin (Sigma) for 2 h at 378C. Per well 1610 5 puri®ed splenic Tcells were plated in triplicate in RPMI 1640 supplemented with 10% FCS, 2 mM L-glutamine, 50 mM b-mercaptoethanol, 100 IU penicillin, 100 mg/ml streptomycin, and 50 mg/ml gentamicin. Cells were pulsed for 8 h with 3 H-methyl thymidine (Amersham) and were harvested and counted (Betaplate Counter/Wallac) at various time points.
Immunoprecipitations, Western blotting, kinase assays and antibodies
Single cell suspensions of lymphoid tissues were prepared as described (MoÈ roÈ y et al., 1993) . Protein extracts were loaded and separated on SDS ± PAGE, transferred onto NCmembranes and the protein of interest detected as described previously (Schmidt et al., 1998) . Tissue samples of tumors were lysed using WCE-buer and micro pistills. Protein lysate concentrations were determined by Bradford assay and equal amounts of proteins were used for Western blotting (30 mg), immunoprecipitations (100 mg) and kinase assays (200 mg).
The following primary antibodies were used: against p21 (M-19), p27 (C-19), p107 (C-18), p130 (C-20), cdk2 (M2), human cyclinE (C-19 or HE12), mouse cyclinE (M-20) (all from Santa Cruz); p27 (DCS-72, generously provided by J Bartek); pRb (G3-245, Pharmingen) and CDK2 (Clontech). As secondary antibodies were used anti-rabbit IgG, HRPlinked, anti-mouse IgG, HRP-linked (both NEB) or donkeyanti-mouse IgG, peroxidase conjugated (Dianova).
For immuno-precipitation the lysate volume equivalent to 100 mg of protein was dissolved in 1 ml of Dignam D-buer (20 mM HEPES pH 7.9, 20% glycerol, 0.1% NP-40, 75 mM NaCl, 100 mM KCl, 0.2 mM EDTA, 3% BSA) and precleared with a 40 ml of a pre-equilibrated proteinAsepharose slurry for 30 min. The supernatant was then incubated with 0.2 mg of the respective antibody for 30 min and 30 ml of a pre-equilibrated 50% (v/v) proteinA-sepharose slurry for another 90 min. The sepharose beads were sedimented and washed three times with incubation buer (20 mM HEPES pH 7.9, 75 mM KCl, 2.5 mM MgCl 2 , 1 mM DTT, 0.1% NP-40, 0.5 mM PMSF, 1 mg/ml aprotinin, 1 mg/ ml pepstatinA, 1 mg/ml leupeptin, 1 mM Na 3 VO 4 ) and resuspended in 46 SDS-gel loading buer (62 mM Tris pH 6.8, 2% (w/v) SDS, 10% (v/v) glycerol, 5% (v/v) b-mercapto ethanol, 0.005% (w/v) bromphenol blue). All above mentioned incubations were carried out at 48C and constant movement using a head-over-tail-rotator. To assay CDK2-or cyclinE-linked kinase activity, the respective immune complexes from 200 mg protein per sample were precipitated as described above, washed three times in incubation buer, once in 10 mM Tris pH 7.5 and resuspended in 40 ml kinase buer (50 mM Tris pH 7.5, 10 mM MgCl 2 , 1 mM DTT, 0.5 mM PMSF, 50 mg/ml histone H1). Reactions were performed by adding 5 ml kinase buer without histone H1 but including 950 mM ATP and 10 mCi [ 32 P]g-ATP and incubating the total reaction volume at 378C for 15 min, terminated by addition of 25 ml of SDS ± gel loading buer. Kinase reactions were subjected to SDS ± PAGE and subsequently analysed.
MNU treatment
Mice comprising all three transgenic lines and non transgenic age matched littermates were given a single dose of 50 mg MNU (Sigma) per kg body weight i.p. at the age of 6 weeks. The animals were observed over a time period of 220 days for the development of lymphoma and were sacri®ced when moribund.
Detection of Ki-ras codon 12 mutations by PCR ± RFLP
The detection of the Ki-ras G to A mutation in the second position of codon 12 was performed as described at Zaidi et al. (1995) . In brief, 100 ng of genomic DNA was used for selective PCR ampli®cation of the ®rst exon of the Ki-ras oncogene using the primers P1 (5'-AACTTGTGGTGGTTG-GACCTG-3') and P2 (5'-AGCGTTACCTCTATCGTAGG-3'). This ampli®cation step of a 106 bp product created a BstNI restriction site by primer P1 in wild type sequences while the presence of a mutation in the second position of codon 12 led to a disruption of the BstNI restriction site. The PCR ampli®cation product was subjected to digestion by BstNI (NEB) and separated on a 4% agarose gel. Wild type K-ras sequences were cut by BstNI generating 86 and 20 bp fragments while mutated sequences were left intact. Genomic DNA from each tumor was analysed four independent times to ensure the detection of the mutated allele.
